In the early 1980s, the oncogene field was in transition. The biological properties of more than 20 oncogenes had been described in animal tumor models and cell transformation assays. Attention was shifting to the question of how these genes actually function. In a few cases, it was obvious. The v-Sis protein (encoded by the transforming gene of simian sarcoma virus) was shown to be related to platelet-derived growth factor and erbB (the oncogene from avian erythroblastosis virus) was found to encode a receptor for epidermal growth factor. The transforming Ras protein was known to bind GTP. This put Ras in a class with the classical signal transducing G-proteins, elongation factors and tubulin but did not clarify its mechanism of action.
The biochemical analysis that was needed to answer such questions was still in its early stages when I decided to enter the field. Two main questions were being addressed: first, how do oncogenic proteins differ from their normal cellular counterparts? This question involved comparison of biochemical properties of normal and mutant proteins -a relatively logical process, and one that was made practical by the development of recombinant methods of producing these proteins. Second, how do these proteins transform cells? This was more of a guessing game. For Ras, it meant a long and relatively fruitless search for proteins that interact with Ras in its active state, and could therefore be Ras 'effectors'.
It was clear that Ras plays a major part in human cancer; by 1983, activating mutations in ras genes (single amino acid changes that seemed to make the mutant Ras proteins overactive) had been described in a variety of cell lines and tumors. (And this was before PCR had even been invented.) To me, with a degree in biochemistry and a job in a biotechnology company, it seemed an ideal moment to apply biochemistry to the question of Ras function. This was a real turning point for me. In 1984, I wound down my work on mammalian expression systems and characterization of β-interferon and geared up to enter the Ras field.
The attention of my group was focussed on the biochemical properties of normal and oncogenic forms of Ras proteins produced in Escherichia coli. We were inspired and encouraged by four papers that revealed a dramatic difference between the two: the normal Ras protein could hydrolyze GTP to GDP; an oncogenic mutant (glycine to valine at codon 12), could not. This lead to a beautifully simple model. Ras proteins are simple switches. They are on when bound to GTP, and off when bound to GDP. Normal Ras turns itself off by converting GTP to GDP through its built-in GTPase activity; oncogenic Ras is stuck in the on position because its built-in GTPase is defective (see Figure 1 ). This brilliant model was inspiring but also provocative because it raised further questions. Most troubling to us was the fact that the mutant protein did, in fact, retain some GTPase activity: it was only about 8-fold less active than wild-type Ras. This hardly seemed sufficient to account for its awesome transforming power. Moreover, the mutant we were working on, the aspartate-12 mutant, was just as powerful at transforming cells yet it was only about 3-fold less active than wild-type Ras in hydrolyzing GTP. We therefore started to wonder whether the GTPase model needed some modification.
A strong prediction of the model was that normal Ras should be in the off state (bound to GDP) in normal cells, whereas the oncogenic mutant should mostly be in the on state (bound to GTP). Using various technical tricks and an awful lot of radioactive phosphorous, we confirmed this.
But in the process, we discovered that the aspartate-12 mutant was fully loaded with GTP, just like the valine-12 mutant, even though its GTPase activity as measured in the test tube was not much different Magazine R673
Figure 1
Model for the Ras protein switch mechanism, which is defective in cells expressing mutant Ras proteins. This led to experiments that identified GAP, the GTPase-activating protein. GAP, as the first protein identified that regulates a protooncogene, represented an early step in the process of dissecting signal transduction pathways. Others used it to define the rules of engagement with tyrosine phosphoproteins and it was found to be related to the gene responsible for neurofibromatosis type 1. Now it's known that virtually all Ras-like proteins, as well as classical G-proteins, are controlled by their own GAPs.
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These were great times for biochemists and molecular biologists; the parallel development of oncogene biology and recombinant DNA offered many opportunities to make useful contributions. And the geneticists who started the oncogene revolution were by no means left in the dust. Dissection of signalling pathways and oncogene function relied heavily on genetic model systems. In fact, the research groups that made most progress in this period contained each of these disciplines, and the collegiate interactions among specialists in each area has been one of the many pleasures of working in this field. If all these efforts lead to a new cancer therapy, that would be the greatest pleasure of all. [6] . But in ABDs they occur in tandem repeats and share only about 30% identical residues with the CH domains of the calponin family. The first and second CH domains in ABDs differ not only in sequence, but also markedly in their affinities for actin, as shown for α-actinin [7] . Further, the amino-terminal CH domains of utrophin and dystrophin are able to bind to F-actin, whereas the carboxy-terminal CH domains bind F-actin with very low affinity or not at all ( [8] ; S.J.W., unpublished observations).
Although IQGAP is able to cross-link F-actin in vitro and localises to membrane ruffles of cultured cells [9] , no conclusive evidence has been brought forward for the direct association of a single CH domain with F-actin. Instead, we have shown that the single CH domain of CaP [10] , as well as that of the CaP-related protein SM22 (R Mital, M.G., unpublished observations), fails to target to either stress fibres or membrane ruffles of transfected fibroblasts, and that two independent actinbinding sites outside the CH domain are responsible for F-actin binding in CaP [10] . Furthermore, a bacterially expressed construct corresponding to the CH domain of The editors of Current Biology have invited a number of biologists to reveal the papers that have influenced them most profoundly in their careers. These brief essays are being published in the Turning points series. If you have any comments, or ideas arising from this series, we shall be happy to consider them.
CaP and comprising residues 28-134 does not bind to F-actin in an in vitro sedimentation assay (S.J.W., unpublished observations).
We have also found that Vav induces and associates with peripheral and dorsal membrane ruffles, but not filopodia, and that deletion of the amino-terminal CH domain does not alter its localisation pattern (W. Kranewitter, M.G., unpublished observations). Together, these results indicate that the single amino-terminal CH domain is neither sufficient nor necessary for actin binding of CaP [10] and imply that single CH domains are unlikely to serve as autonomous actintargeting motifs in monomeric signalling molecules. Nevertheless, based on F-actin co-sedimentation studies using truncated glutathione-S-transferase (GST) fusion proteins, two groups [3, 11] have demonstrated recently that the actin-binding activity for IQGAP 1 and its putative yeast homologue Iqg1 resides within the CH-domain-embracing aminoterminal 216 and 538 residues, respectively. The CH domain occupies only 100 of these residues. The ability to cross-link F-actin depends on the potential of IQGAP to oligomerise via the IQGAPspecific repeats, pointing towards a possible requirement for a second domain for actin binding in vivo. It is thus conceivable that single CH domains can cooperate synergistically with other modules to mediate F-actin binding.
In view of current misapprehensions about CH domains, we have recently analysed the sequences of all CH-domaincontaining proteins currently available. The analysis has shown that amino-terminal (type 1), carboxy-terminal (type 2), and single CH domains group into individual 'families' [12] . Most importantly, we were able to show that all single CH-domain-containing proteins, namely CaP, SM22, IQGAP and Vav, display a higher degree of sequence similarity in their respective CH domains to the members of the same subfamilies than to either of the CH domains found in any ABD. Hence, the function of a CH domain in signalling molecules is more likely to be gleaned from studies on CaP than on the ABDs of actin cross-linking proteins and related proteins.
We thus propose that CH domains display a different function when present in single as compared to tandem motifs, and that different classes of proteins contain CH domains of different 'quality'. A similar phenomenon has been reported for another 100 amino acid protein module, the pleckstrin homology (PH) domain [13, 14] . The two PH domains of the archetypal pleckstrin, situated at the aminoterminal and carboxy-terminal ends of the molecule, are functionally divergent, and PH domains from other proteins fail to functionally substitute for the amino-terminal PH domain in pleckstrin itself [15] .
We conclude that a careful reevaluation of CH domains is required with respect to actinbinding properties, especially for monomeric proteins that contain only one CH domain. 
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